Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Navarixin - Ligand Pharmaceuticals/Merck & Co.

Next Previous
Drug Profile

Navarixin - Ligand Pharmaceuticals/Merck & Co.

Alternative Names: MK-7123; PS-291822; SCH 527123; SCH 5271234

Latest Information Update: 05 Nov 2023

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Pharmacopeia; Schering-Plough
  • Developer Ligand Pharmaceuticals; Merck & Co
  • Class Anti-inflammatories; Antineoplastics; Benzamides; Cyclobutanes
  • Mechanism of Action Interleukin 8A receptor antagonists; Interleukin 8B receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Solid tumours
  • Discontinued Asthma; Chronic obstructive pulmonary disease; Psoriasis

Most Recent Events

  • 19 May 2021 Merck completes phase II trial in Solid tumours (Combination therapy, Late-stage disease, Metastatic disease, Second-line therapy or greater) in USA, Australia, Canada, South Korea, Israel (PO) (NCT03473925)
  • 19 Feb 2021 Navarixin is still in phase II trial for Solid tumours (Combination therapy, Late-stage disease, Metastatic disease, Second-line therapy or greater) in USA, Israel (PO) (NCT03473925)
  • 22 Jan 2021 Merck & Co. completes enrolment in its phase II trial for Solid tumours (Combination therapy, Late-stage disease, Metastatic disease, Second-line therapy or greater) in USA, Australia, Canada, Israel, South Korea (PO) (NCT03473925)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top